The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
 
Timothy Anthony Yap
Honoraria - AstraZeneca
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Atrin Pharmaceuticals; Clovis Oncology; EMD Serono; Ignyta; Janssen; Pfizer; Tesaro
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Clearbridge Biomedics; Pfizer; Roche; Vertex
Patents, Royalties, Other Intellectual Property - Employee of The Institute of Cancer Research, which has a financial interest in the discovery and development of anticancer drugs (Inst)
Travel, Accommodations, Expenses - Vertex
 
Solmaz Sahebjam
Honoraria - Bristol-Myers Squibb; Merck Serono
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono
Research Funding - Bristol-Myers Squibb; Cortice Bioscience; Merck Serono
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Vi Kien Chiu
No Relationships to Disclose
 
Emrullah Yilmaz
No Relationships to Disclose
 
Sergey Efuni
Employment - Kyowa Hakko Kirin
 
Dmitri O. Grebennik
Employment - Kyowa Hakko Kirin
 
Agron Collaku
Employment - Kyowa Hakko Kirin
 
Eniola Ogunmefun
Employment - Kyowa Hakko Kirin
 
Yi Liu
Employment - Kyowa Hakko Kirin
 
Tomonori Tayama
Employment - Kyowa Hakko Kirin
 
Robert Raymond Latek
Employment - Kyowa Hakko Kirin
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Olivier Rixe
Research Funding - Bexion; Kyowa Hakko Kirin; Leap Therapeutics; Medimmune; Newlink Genetics; Pfizer; Regeneron; Rgenix; Seagen
Travel, Accommodations, Expenses - Bexion